Sponsored by
A new study shows adding berzosertib (an ATR inhibitor) to radiation appears to make H3K27-altered diffuse midline glioma more sensitive to treatment by blocking tumor DNA repair, leading to greater tumor cell death in preclinical models. This suggests a promising strategy to enhance radiotherapy effectiveness, but it remains experimental and requires clinical trials to confirm safety and benefit for patients.